MICROBIOLOGY LECTURE 10: CORONAVIRUSES

A. THE CORONAVIRUSES
  1. General Properties

    • Coronaviruses are large, enveloped RNA viruses.

    • Known to cause common colds and may lead to lower respiratory tract infections (e.g., pneumonia) and gastrointestinal infections in infants.

    • Highest mortality rates observed during the Delta variant due to severe pneumonia caused by these viruses.

    • Can present with diarrhea, particularly in infants; adults may experience diarrhea during infection, notably during the COVID-19 pandemic.

    • A novel coronavirus was identified as the cause of a worldwide outbreak of severe acute respiratory syndrome (SARS) in 2003.

    • Human coronaviruses are difficult to culture, resulting in poorer characterization.

    • Nucleocapsid: contains RNA and polymerase enzyme.

    • Figure 1: Structure of SARS-CoV-2

B. GENERAL PROPERTIES
  • Characteristic: Description

    • Virion: Spherical, 120-160 nm in diameter with a helical nucleocapsid.

    • Genome: Single-stranded RNA, linear, non-segmented, positive sense, 27-32 kb, capped, and polyadenylated, infectious.

    • Proteins: Two glycoproteins and one phosphoprotein; some coronaviruses also contain a third glycoprotein known as hemagglutinin esterase.

    • Envelope: Contains large, widely spaced, club- or petal-shaped spikes.

    • Replication: Occurs in the cytoplasm; particles mature by budding into the endoplasmic reticulum and Golgi apparatus.

  • Outstanding Characteristics:

    • Causes colds, SARS, and MERS.

    • Displays a high frequency of recombination (e.g., spike protein changes or mutations).

    • Difficult to grow in cell culture.

C. CLASSIFICATION
  • Coronaviridae is one of two families within the order Nidovirales, alongside Arteriviridae.

  • Classification Characteristics:

    • Particle morphology

    • Unique RNA replication strategy

    • Genome organization

    • Nucleotide sequence homology

  • Subfamilies:

    1. Coronavirinae

    2. Torovirinae

  • Genera in Coronaviridae:

    • Five genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, Bafinivirus, and Torovirus.

    • The Alphacoronavirus, Betacoronavirus, and Torovirus primarily include viruses that infect humans.

    • Toroviruses are widespread in ungulates and are associated with diarrhea.

  • Figure 2: Characterization and replication cycle of coronaviruses.

    • Attachment is primarily to the ACE-2 receptor through the glycoprotein.

    • Following attachment, RNA is released, leading to replication and maturation.

D. TRANSCRIPTION
  1. Unique Biochemical Mechanisms:

    • Ribosome frameshifting during genome translation.

    • Synthesis of both genomic and multiple subgenomic RNA species.

    • The hallmark is the production of subgenomic mRNAs (HE, S, E, M, N, plus non-structural proteins).

    • These mRNAs are generated from the original RNA genome and contain sequences from both ends.

    • Mechanism:

      • Binds to ACE2 receptor  Conformational changes occur, altering the plasma membrane, facilitating receptor-mediated endocytosis, pulling the virus into the cytoplasm, resulting in uncoating  the genomic RNA (+) remains and is utilized to create RNA-dependent RNA polymerase.

      • The (+) strand is replicated into (-) strand RNA.

E. REPLICATION
  • Occurs in the cytoplasm:

    • Progeny virions are produced via the secretory rough endoplasmic reticulum (RER), Golgi apparatus, and subsequently released through exocytosis.

    • The host cell machinery, primarily the ribosome, translates the RNA strand into several open reading frames (ORFs).

  • Figure 3: Coronavirus replication cycle.

  • Attachment: Virions bind to specific receptor glycoproteins/glycans through the spike protein.

  • Penetration and uncoating occur via S protein-mediated fusion between the viral envelope and either the plasma membrane or endosomal membranes.

  • Gene 1 from the viral genomic RNA is translated into a polyprotein, which is then processed to yield the transcriptase-replicase complex.

  • The genomic RNA serves as a template to create negative-stranded RNAs, which further synthesize both full-length genomic RNA and subgenomic mRNAs.

  • Each mRNA is translated to produce only the proteins encoded by the 5’ end of the mRNA, including nonstructural proteins (NSPs).

  • The N protein and newly synthesized genomic RNA assemble to form helical nucleocapsids.

  • The membrane glycoprotein M is integrated into the endoplasmic reticulum and anchored in the Golgi apparatus.

  • The nucleocapsid, consisting of the N protein and genomic RNA, binds to the M protein at the budding compartment (ERGIC).

  • E and M proteins interact to induce the budding of virions, encapsulating the nucleocapsid.

  • Spike (S) and hemagglutinin esterase (HE) glycoproteins are glycosylated, trimerized, associated with M protein, and incorporated into maturing virus particles.

  • Release: Virions are released via exocytosis-like fusion of vesicles with the plasma membrane, although some virions may remain attached to the plasma membranes of infected cells.

  • The entire replication cycle occurs within the cytoplasm.

F. CORONAVIRUS INFECTION IN HUMANS
  1. Pathogenesis:

    • Coronaviruses demonstrate a tropism for epithelial cells within the respiratory system (RES) and the gastrointestinal tract (GIT).

    • The SARS coronavirus can also infect epithelial cells lining the salivary gland ducts.

    • The 2003 SARS outbreak was characterized by significant respiratory illness, including pneumonia and progressive respiratory failure.

    • The virus has been detected in various organs, including the kidney, liver, small intestine, and stool.

    • The SARS virus likely originated from a nonhuman host (possibly bats), went through an amplification stage in palm civets, and was transmitted to humans, notably in live animal markets.

    • Chinese horseshoe bats are known as natural reservoirs for SARS-like coronaviruses.

    • Figure 5: COVID-19 symptoms.

  2. Clinical Findings:

    • Common symptoms associated with Coronavirus (COVID-19/SARS-CoV-2) include:

      • Cough

      • Shortness of breath or difficulty breathing

      • Fever or chills

      • Muscle or body aches

      • Vomiting or diarrhea

      • New loss of taste or smell

    • The incubation period ranges from 2 to 5 days, with symptoms typically lasting about 1 week.

    • Disease Severity (in patients with confirmed COVID-19):

    1. Non-Severe: Absence of signs of severe or critical disease.

    2. Severe: Oxygen saturation <90% on room air; signs of pneumonia; severe respiratory distress.

    3. Critical: Requires life-sustaining treatment; may involve acute respiratory distress syndrome, sepsis, or septic shock.

  3. Immunity:

    • The immune response against the surface projection antigen is crucial for protection against infection.

    • Resistance to reinfection may last for several years; however, reinfections with similar strains are common.

    • More than 95% of patients with SARS developed an antibody response against viral antigens, detectable using fluorescent antibody tests or enzyme-linked immunoassays (ELISAs).

  4. Laboratory Diagnosis:

    • Antigen and Nucleic Acid Detection:

      • COVID-19 antigens can be identified in respiratory secretions via ELISA tests if quality antiserum is available.

      • Enteric coronaviruses may be detected through stool sample examinations facilitated by electron microscopy.

      • PCR assays play a significant role in detecting coronavirus nucleic acid in both respiratory and stool samples.

      • SARS virus RNA was notably detectable in plasma via PCR, especially between days 4 and 8 post-infection.

    • Isolation and Identification of Virus:

      • Isolation of human coronaviruses in cell culture remains challenging, but the SARS virus was successfully isolated from oropharyngeal specimens using Vero monkey kidney cells.

    • Serology:

      • ELISA, indirect immunofluorescent antibody assays, and hemagglutination tests aid in serological evaluations.

      • Due to the difficulty of isolating the virus, serodiagnoses using acute and convalescent sera are recognized as practical methods for confirming coronavirus infections.

      • Serologic identification of strain 229E infections is feasible through passive hemagglutination tests where red blood cells coated with coronavirus antigen agglutinate in the presence of antibody-containing sera.

    • Figure 6: COVID-19 (SARS-CoV-2) serologic testing process.

      • The test begins by placing the patient’s blood sample at one end of a test strip (1). The strip contains pads that absorb the blood sample, allowing it to flow via capillary action.

      • At the initial end, the conjugate pad contains SARS-CoV2 “S” protein attached to colored probes.

      • If the blood sample holds SARS-CoV2 antibodies, they will tag onto the “S” protein color probes.

      • As the sample advances along the strip, the colored “S” protein attached to any SARS-CoV2 antibodies will pass a detection line designed for IgM antibodies, with visible color lines appearing in this region if IgM is present (2).

      • The sample continues towards a detection line for IgG antibodies, operating similarly (3).

      • A control line confirms that the test functions properly and verifies operational accuracy.

References
  • Zara, R. (2026). Coronaviruses [PPT].

  • Riedel, S. et al (2019). Jawetz, Melnick, & Adelberg's Medical Microbiology (28th ed.). New York: Mc Graw Hill.

  • Ackerman, S. (2020). Research America. Explained: How a COVID-19 Serology Test Works And Obstacles to its Use.